BELANOFF JOSEPH K 4
4 · CORCEPT THERAPEUTICS INC · Filed Oct 3, 2025
Insider Transaction Report
Form 4
BELANOFF JOSEPH K
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-10-01$85.16/sh−31,190$2,656,265→ 2,784,564 total(indirect: By Trust) - Sale
Common Stock
2025-10-01$85.67/sh−3,194$273,618→ 2,781,370 total(indirect: By Trust) - Sale
Common Stock
2025-10-01$84.29/sh−5,616$473,370→ 2,815,754 total(indirect: By Trust)
Footnotes (5)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
- [F2]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.58 to $84.53 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F3]Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
- [F4]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.5875 to $85.575 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F5]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.63 to $85.785 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.